Indian Drugmakers
- All
- News
- Videos
-
Fire At Pharma Lab In Andhra Pradesh Kills 4
Indian drugmaker Laurus Labs said on Tuesday that four of its employees died following a flash fire in a room in a manufacturing block of its plant in Visakhapatnam, Andhra Pradesh.
-
"Test Solvents": Karnataka Tells Drugmakers After WHO Cough Syrup Alert
Drugs Control Department has directed drug manufacturers that certificate of analysis of glycerin and propylene glycol procured in the last one year should be submitted within seven days
-
South Korea's Enzychem To Make Cadila's COVID-19 Shot
South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the Indian drugmaker said on Wednesday.
-
2 Indian Firms Seek To End Current Trials Of Merck's Anti-Covid Pill
Two drugmakers in the country have requested permission to end their late-stage trials on Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients.
-
Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
-
If India's Zydus Cadila Shot Is Cleared, It Will Set A Global First
Indian drugmaker Zydus Cadila said on Thursday it has applied for emergency use approval of its three-dose COVID-19 vaccine that showed efficacy of 66.6% in an interim study and could become the second home-grown shot if regulators consent.
-
India's Zydus Cadila Seeks Nod For Its Covid Vaccine ZyCoV-D
Indian drugmaker Zydus Cadila said on Thursday it has applied to the country's drug regulator for emergency use approval of its COVID-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
India, Pfizer Seek To Bridge Dispute Over Vaccine Indemnity: Report
Pfizer and the Indian government are seeking to resolve tensions over a demand by the US drugmaker for legal protection from any claims linked to the use of its COVID-19 vaccine in one of the world's biggest markets, two sources told Reuters.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Indian Drugmaker To Produce 200 Million Doses, Says Russia's Sputnik V Developer
The developer of Russia's Sputnik V coronavirus vaccine said Friday it had signed a partnership with an India-based drugmaker for the production of 200 million doses of the two-dose jab.
-
Indian Drugmaker To Pay $50 Million Fine In US For Irregularities
An Indian drug manufacturer has agreed to plead guilty to concealing and destroying records prior to a 2013 US Food and Drug Administration's inspection of its plant and pay USD 50 million in fines and forfeiture, the Department of Justice has announced.
-
Indian Drugmaker Aims For 60 Crore Johnson & Johnson Vaccine Doses A Year
Pharmaceutical company Biological E Ltd is looking to contract-manufacture roughly 600 million doses of Johnson and Johnson's COVID-19 vaccine candidate annually, Mahima Datla, managing director of the privately-held company said on Wednesday.
-
Fire At Pharma Lab In Andhra Pradesh Kills 4
Indian drugmaker Laurus Labs said on Tuesday that four of its employees died following a flash fire in a room in a manufacturing block of its plant in Visakhapatnam, Andhra Pradesh.
-
"Test Solvents": Karnataka Tells Drugmakers After WHO Cough Syrup Alert
Drugs Control Department has directed drug manufacturers that certificate of analysis of glycerin and propylene glycol procured in the last one year should be submitted within seven days
-
South Korea's Enzychem To Make Cadila's COVID-19 Shot
South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the Indian drugmaker said on Wednesday.
-
2 Indian Firms Seek To End Current Trials Of Merck's Anti-Covid Pill
Two drugmakers in the country have requested permission to end their late-stage trials on Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients.
-
Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
-
If India's Zydus Cadila Shot Is Cleared, It Will Set A Global First
Indian drugmaker Zydus Cadila said on Thursday it has applied for emergency use approval of its three-dose COVID-19 vaccine that showed efficacy of 66.6% in an interim study and could become the second home-grown shot if regulators consent.
-
India's Zydus Cadila Seeks Nod For Its Covid Vaccine ZyCoV-D
Indian drugmaker Zydus Cadila said on Thursday it has applied to the country's drug regulator for emergency use approval of its COVID-19 vaccine and that it plans to manufacture up to 120 million doses of the shot annually.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
India, Pfizer Seek To Bridge Dispute Over Vaccine Indemnity: Report
Pfizer and the Indian government are seeking to resolve tensions over a demand by the US drugmaker for legal protection from any claims linked to the use of its COVID-19 vaccine in one of the world's biggest markets, two sources told Reuters.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Indian Drugmaker To Produce 200 Million Doses, Says Russia's Sputnik V Developer
The developer of Russia's Sputnik V coronavirus vaccine said Friday it had signed a partnership with an India-based drugmaker for the production of 200 million doses of the two-dose jab.
-
Indian Drugmaker To Pay $50 Million Fine In US For Irregularities
An Indian drug manufacturer has agreed to plead guilty to concealing and destroying records prior to a 2013 US Food and Drug Administration's inspection of its plant and pay USD 50 million in fines and forfeiture, the Department of Justice has announced.
-
Indian Drugmaker Aims For 60 Crore Johnson & Johnson Vaccine Doses A Year
Pharmaceutical company Biological E Ltd is looking to contract-manufacture roughly 600 million doses of Johnson and Johnson's COVID-19 vaccine candidate annually, Mahima Datla, managing director of the privately-held company said on Wednesday.
